biostudies-literatureUnknown8(3)Mao-Draayer YNovartis Pharmaceuticals Corporation<h4>Background</h4>Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully understood.<h4>Objective</h4>Investigate fingolimod's temporal effects on immune cell subsets, and safety outcomes.<h4>Methods</h4>In FLUENT, a 12-month, prospective, non-randomized, open-label, phase IV study, adult participants received fingolimod 0.5 mg/day. Changes in immune cell subsets, anti-John Cunningham virus (JCV) antibody index, and serum neurofilament levels were assessed.<h4>Results</h4>165 fingolimod-naive and 217 participants treated for 2-12 years in routine clinical practice were enrolled. Levels of all monitored peripheral lymphocyte subsets were reduced from month 3 in fingolimod-naive participants. GreatesMultiple sclerosis journal - experimental, translational and clinical20552173221115023https://www.ebi.ac.uk/biostudies/studies/S-EPMC9346260biostudies-literatureImmune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study.PMC9346260Han MHSinger BMao-Draayer YElam CWilliams IMBar-Or ACohen JAMeng XFLUENT study investigatorsZiehn MWeiss JLCree BACox GMfalseImmune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study.<h4>Background</h4>Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully understood.<h4>Objective</h4>Investigate fingolimod's temporal effects on immune cell subsets, and safety outcomes.<h4>Methods</h4>In FLUENT, a 12-month, prospective, non-randomized, open-label, phase IV study, adult participants received fingolimod 0.5 mg/day. Changes in immune cell subsets, anti-John Cunningham virus (JCV) antibody index, and serum neurofilament levels were assessed.<h4>Results</h4>165 fingolimod-naive and 217 participants treated for 2-12 years in routine clinical practice were enrolled. Levels of all monitored peripheral lymphocyte subsets were reduced from month 3 in fingolimod-naive participants. Greates2022-01-01T00:00:00Z2022 Jul-Sep2026-07-14T15:52:11.488Z2024-11-09T20:30:29.52ZS-EPMC93462603593692210.1177/20552173221115023